Abstract:Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with dire consequences and in urgent need of improved therapies. Compelling evidence indicates that damage or dysfunction of AT2s is of central importance in the development of IPF. We recently identified a novel AT2 subpopulation characterized by low SFTPC expression but that is enriched for PD-L1 in mice. These cells represent quiescent, immature AT2 cells during normal homeostasis and expand upon pneumonectomy (PNX) and were consequently named injury-activated alveolar progenitors (IAAPs). FGF10 is shown to play critical roles in lung development, homeostasis, and injury repair demonstrated in genetically engineered mice. In an effort to bridge the gap between the promising properties of endogenous Fgf10 manipulation and therapeutic reality, we here investigated whether the administration of exogenous recombinant FGF10 protein (rFGF10) can provide preventive and/or therapeutic benefit in a mouse model of bleomycin-induced pulmonary fibrosis with a focus on its impact on IAAP dynamics. C57BL/6 mice and SftpcCreERT2/+; tdTomatoflox/+ mice aged 8–10 weeks old were used in this study. To induce the bleomycin (BLM) model, mice were intratracheally (i.t.) instilled with BLM (2 μg/g body weight). BLM injury was induced after a 7-day washout period following tamoxifen induction. A single i.t. injection of rFGF10 (0.05 μg/g body weight) was given on days 0, 7, 14, and 21 after BLM injury. Then, the effects of rFGF10 on BLM-induced fibrosis in lung tissues were assessed by H&E, IHC, Masson's trichrome staining, hydroxyproline and Western blot assays. Immunofluorescence staining and flow cytometry was used to assess the dynamic behavior of AT2 lineage-labeled SftpcPos (IAAPs and mature AT2) during the course of pulmonary fibrosis. We observed that, depending on the timing of administration, rFGF10 exhibited robust preventive or therapeutic efficacy toward BLM-induced fibrosis based on the evaluation of various pathological parameters. Flow cytometric analysis revealed a dynamic expansion of IAAPs for up to 4 weeks following BLM injury while the number of mature AT2s was drastically reduced. Significantly, rFGF10 administration increased both the peak ratio and the duration of IAAPs expansion relative to EpCAMPos cells. Altogether, our results suggest that the administration of rFGF10 exhibits therapeutic potential for IPF most likely by promoting IAAP proliferation and alveolar repair.

Inhibition of Pulmonary Fibrosis in Mice by Cxcl10 Requires Glycosaminoglycan Binding and Syndecan-4

Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10

Cxcl6 Antibody Neutralization Prevents Lung Inflammation and Fibrosis in Mice in the Bleomycin Model

G-CSF Inhibits Pulmonary Fibrosis by Promoting BMSC Homing to the Lungs via SDF-1/CXCR4 Chemotaxis

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Regulation of Pulmonary Fibrosis by Chemokine Receptor CXCR3.

CXCL4 drives fibrosis by promoting several key cellular and molecular processes

CCL17 Drives Fibroblast Activation in the Progression of Pulmonary Fibrosis by Enhancing the TGF-β/Smad Signaling.

A single injection of bleomycin reduces glycosaminoglycan sulfation up to 30 days in the C57BL/6 mouse model of lung fibrosis

FGF10 Therapeutic Administration Promotes Mobilization of Injury-Activated Alveolar Progenitors in a Mouse Fibrosis Model

Chemokine (C‐X‐C motif) ligand 14 contributes to lipopolysaccharide‐induced fibrogenesis in mouse L929 fibroblasts via modulating PPM1A

A Novel Single-Chain-Fv Antibody Against Connective Tissue Growth Factor Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice

IFN-γ-Inducible Protein-10 Attenuates Bleomycin-Induced Pulmonary Fibrosis Via Inhibition of Angiogenesis

Cangrelor Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting Platelet Activation in Mice.

Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis

The interplay of Cxcl10+/Mmp14+ monocytes and Ccl3+ neutrophils proactively mediates silica-induced pulmonary fibrosis

CXCL16/CXCR6 Axis Promotes Bleomycin-Induced Fibrotic Process in MRC-5 Cells Via the PI3K/AKT/FOXO3a Pathway.

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice

Inhibition of Wnt/β-catenin Signaling Suppresses Bleomycin-Induced Pulmonary Fibrosis by Attenuating the Expression of TGF-β1 and FGF-2.

Inhibition of sphingosine 1-phosphate receptor 3 ameliorates bleomycin-induced pulmonary fibrosis by suppressing macrophage M2 polarization

Synergistic Protection of Schizandrin B and Glycyrrhizic Acid Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β1/Smad2 Pathways and Overexpression of NOX4.